Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

Status:
Not yet recruiting

Trial end date:
2024-04-30

Target enrollment:

Participant gender:

To assess the safety and tolerability of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib

Phase 1

Cellenkos, Inc.